Development asset linked to Wuhan Humanwell Innovative in public FDA and regional records.
pharma · Advanced Solid Tumors
Wuhan Humanwell Innovative
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Wuhan Humanwell Innovative drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Wuhan Humanwell Innovative pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Wuhan Humanwell Innovative drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Wuhan Humanwell Innovative in public FDA and regional records.